Cdt1 is differentially targeted for degradation by anticancer chemotherapeutic drugs. - Wikidata - wikimedia - TriplyDB

Cdt1 is differentially targeted for degradation by anticancer chemotherapeutic drugs.

Cdt1 is differentially targeted for degradation by anticancer chemotherapeutic drugs.

http://www.wikidata.org/entity/Q34222698

about

The stress phenotype makes cancer cells addicted to CDT2, a substrate receptor of the CRL4 ubiquitin ligase.Checkpoint kinase ATR phosphorylates Cdt2, a substrate receptor of CRL4 ubiquitin ligase, and promotes the degradation of Cdt1 following UV irradiation.Mitotic UV irradiation induces a DNA replication-licensing defect that potentiates G1 arrest response.Mismatch repair proteins recruited to ultraviolet light-damaged sites lead to degradation of licensing factor Cdt1 in the G1 phase.REGγ deficiency promotes premature aging via the casein kinase 1 pathway.PIP degron proteins, substrates of CRL4Cdt2, and not PIP boxes, interfere with DNA polymerase η and κ focus formation on UV damage Cell cycle staging of individual cells by fluorescence microscopy.Generation of cell-based systems to visualize chromosome damage and translocations in living cells.

P2860

Q34227548-79C43A50-2C38-47BE-9C43-D57B74DC80EA Q34431295-73170002-C46E-446D-9C41-C2589FF4DC1E Q35583775-E32D780C-5373-466C-B958-BE6328E97649 Q36302154-3C8CEB2E-5DDD-4E89-AF48-E0C94D3C8400 Q36990873-40667F25-DD71-4743-BECA-C4003CBAF5D2 Q37680370-C9DCD354-97A7-46A1-8C86-A95A1C4AD40B Q38915258-3A9994BF-D191-4553-9006-7AD2081E0281 Q38953390-63CB7419-7191-49E7-9BDD-D2F2E617A285

P2860

Cdt1 is differentially targeted for degradation by anticancer chemotherapeutic drugs.

http://www.wikidata.org/entity/Q34222698

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Cdt1 is differentially targeted for degradation by anticancer chemotherapeutic drugs.

@ast

Cdt1 is differentially targeted for degradation by anticancer chemotherapeutic drugs.

@en

Cdt1 is differentially targeted for degradation by anticancer chemotherapeutic drugs.

@nl

type

label

Cdt1 is differentially targeted for degradation by anticancer chemotherapeutic drugs.

@ast

Cdt1 is differentially targeted for degradation by anticancer chemotherapeutic drugs.

@en

Cdt1 is differentially targeted for degradation by anticancer chemotherapeutic drugs.

@nl

prefLabel

Cdt1 is differentially targeted for degradation by anticancer chemotherapeutic drugs.

@ast

Cdt1 is differentially targeted for degradation by anticancer chemotherapeutic drugs.

@en

Cdt1 is differentially targeted for degradation by anticancer chemotherapeutic drugs.

@nl

P1433

Q34222698-FA33CD98-C471-496D-BF46-B16A1C6C0F1F

P1476

Q34222698-B560638F-C9B3-4B2B-A774-8A171E43F763

P2093

Q34222698-49B9B4E4-9310-4039-BAB2-AD91CE43056D

Q34222698-4BD3BF43-D75B-4504-966A-CB898FB85F72

Q34222698-A09A0B4F-3DE8-4F97-96DA-114582926308

Q34222698-C46FEA9A-FB20-4603-A560-328F90FECB5B

Q34222698-FD6CDEDB-7645-4B0F-A57E-0C6DED076FC6

P2860

Q34222698-03D8D190-89B6-452C-AC3D-586C7E234CE0

Q34222698-0683E2CB-F286-42FD-AD30-D49D1CB3207F

Q34222698-08950FA0-33B4-453A-BB81-7D529EE30444

Q34222698-095B7E47-A51F-47BF-9B85-36CA1B428A9C

Q34222698-0F7B8C13-48A9-443D-B386-8BA9203F09AA

Q34222698-1442E8D1-231B-4C54-9222-4B509CA2675B

Q34222698-1684FA2E-B4F2-4D6C-B777-2E20731B1E8B

Q34222698-192EE468-2B93-4967-9819-5D2A93DEE6B5

Q34222698-1D811E38-870F-4943-BD9D-A4F9C8357472

Q34222698-1DFE9891-770B-49E2-805A-1EA9C5118FEC

P304

Q34222698-43A79720-411D-441A-96D6-CA9DB5A70BDE

P31

Q34222698-450B9A65-B3C6-4923-843E-F03C904E925E

P356

Q34222698-B1E59AEB-7247-4D40-BC6A-33E2AB0E49A3

P407

Q34222698-061D1702-EFFF-44A4-89E9-6FC85BB4205D

P433

Q34222698-A6435D07-8B96-464E-85C2-C3C1C577914B

P478

Q34222698-A0A50991-CC8C-450F-AF76-850AADDC2E6C

P50

Q34222698-4145F63E-AB17-447A-9598-EC6D7FEBFB0E

Q34222698-8059EC50-18AA-4250-A623-5808CC622764

Q34222698-B7BC520B-7C3C-4975-9CEC-90541E6BB59C

P577

Q34222698-B05CA0CC-89E4-4CE5-B1E7-2E9BC6CCCB04

P5875

Q34222698-54700840-2F2F-49F7-8151-26D436C231AC

P698

Q34222698-C8DC93F9-DFB9-46BC-8B6F-920EB808B892

P921

Q34222698-9A87FBCE-5688-4ADB-9A15-36DDC6F335AE

P932

Q34222698-08AF89BF-46EC-4ACA-A262-8880E7850203

P356

JOURNAL.PONE.0034621

P1433

P1476

Cdt1 is differentially targeted for degradation by anticancer chemotherapeutic drugs.

@en

P2093

Athanasia Stathopoulou

http://www.w3.org/2001/XMLSchema#string

Chariklia Petropoulou

http://www.w3.org/2001/XMLSchema#string

Nickolas Karantzelis

http://www.w3.org/2001/XMLSchema#string

Panagiotis Kotsantis

http://www.w3.org/2001/XMLSchema#string

Zoi Lygerou

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of eukaryotic DNA replication by geminin binding to Cdt1

Cdt1 associates dynamically with chromatin throughout G1 and recruits Geminin onto chromatin

A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1

Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target human Cdt1 for proteolysis.

Selective ubiquitylation of p21 and Cdt1 by UBCH8 and UBE2G ubiquitin-conjugating enzymes via the CRL4Cdt2 ubiquitin ligase complex.

DTL/CDT2 is essential for both CDT1 regulation and the early G2/M checkpoint

Cdt1 phosphorylation by cyclin A-dependent kinases negatively regulates its function without affecting geminin binding

Targeting DNA topoisomerase II in cancer chemotherapy

DNA damage induces Cdt1 proteolysis in fission yeast through a pathway dependent on Cdt2 and Ddb1

XCDT1 is required for the assembly of pre-replicative complexes in Xenopus laevis

P304

e34621

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0034621

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Stavros Taraviras

Vassilis Roukos

Hideo Nishitani

P577

2012-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223961279

http://www.w3.org/2001/XMLSchema#string

P698

22479651

http://www.w3.org/2001/XMLSchema#string

P921

P932

3316709

http://www.w3.org/2001/XMLSchema#string